BELIEVE: Phase III Study of Luspatercept vs Placebo in Beta-Thalassemia

December 1-4, 2018; San Diego, California

Transfusion-dependent adults with beta-thalassemia who received luspatercept were more likely to achieve clinically meaningful reductions in transfusion burden compared with placebo.

Format: Microsoft PowerPoint (.ppt)
File Size: 196 KB
Released: December 4, 2018


Provided by the Annenberg Center for Health Sciences at Eisenhower.

Contact Clinical Care Options

For customer support please email:

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Celgene Corporation
Dova Pharmaceuticals, Inc.
Gilead Sciences
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Takeda Oncology

Related Content

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the expanding treatment options for hemophilia A & B

Stacy Croteau Headshot Stacy E. Croteau, MD, MMS
Program Director
Guy A. Young, MD
Program Director
Released: January 25, 2023

From ASCO GI 2023, preliminary safety and efficacy data from the LEAP-015 study of pembrolizumab + lenvatinib + CT for gastroesophageal cancer, as reported by Clinical Care Options (CCO)

Released: January 25, 2023

Data from ASCO GI 2023 from the SPOTLIGHT trial of zolbetuximab + mFOLFOX6 for CLDN18.2-positive/HER2-negative gastric cancers, as reported by Clinical Care Options (CCO)

Released: January 25, 2023

On-demand webcast of a live symposium chaired by Dr Joyce O’Shaughnessy on biomarker-guided neo/adjuvant therapy for early breast cancer, from Clinical Care Options (CCO)

Joyce O'Shaughnessy, MD Melinda Telli, MD Tiffany A. Traina, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 25, 2023 Expired: January 24, 2024

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings